Camrbidge, MA, USA – Researchers have developed a way to grow human heart tissue that can serve as a model for the upper chambers of the heart, known as the atria. The tissue, derived from human induced pluripotent stem cells (hiPCSs), beats, expresses genes, and responds to drugs in a manner similar to a real human atrium.
The model, described November 8 in the journal Stem Cell Reports, may be useful for evaluating disease mechanisms and drugs for atrial fibrillation – the most common type of arrhythmia.
In contrast to standard 2D culture, the stem-cell-derived cardiomyocytes were cultured in a way that they formed 3D beating heart tissue resembling atrial heart muscle (view video here). Specifically, the cells showed atrial-like gene expression, contractile force, contraction and relaxation kinetics, electrophysiological properties, and pharmacological responses to atrial-selective drugs. According to the authors, the engineered heart tissue could serve as a model of the human atrium for both mechanistic studies of atrial fibrillation and for preclinical drug screening.
"This is the first time that human atrial heart tissue has been generated in vitro from a principally unlimited source of hiPSCs," says first author Marta Lemme of the University Medical Center Hamburg-Eppendorf. "This could be useful both for academic laboratories and the pharmaceutical industry, because to test potential new drugs, we need to generate an in vitro model of atrial fibrillation. And the first step in that is to obtain cells that resemble human atrial cardiomyocytes," Lemme says.
Lemme and senior study author Thomas Eschenhagen of the University Medical Center Hamburg-Eppendorf set out to achieve this goal by generating atrial-like cardiomyocytes from hiPSCs using a vitamin A metabolite called all-trans retinoic acid. This technique involves genetically reprogramming blood or skin cells taken from human donors to an embryonic stem-cell-like state and then treating these immature cells with all-trans retinoic acid to convert them into atrial-like cardiomyocytes.
"But the novelty of this study is the combination of hiPSC differentiation into atrial cardiomyocytes with a 3D environment," Lemme says. "In fact, we showed that the 3D environment favors the differentiation toward an atrial phenotype compared to standard 2D culture. A particular value of our study is the direct comparison of our 3D engineered heart tissue with native human atrial tissue obtained from patients on a molecular and functional level."
More than 33 million people worldwide suffer from atrial fibrillation, and the prevalence is rising. Uncoordinated high-frequency contractions in the atria increase the risk for blood clots, stroke, and heart failure. Unfortunately, existing treatments such as antiarrhythmic drugs have limited efficacy and can cause adverse effects. Moreover, the development of new drugs has been hindered by the difficulty in isolating and maintaining human atrial cardiomyocytes, or heart muscle cells. Animal models have limited predictive power because they do not accurately represent the physiology of human cardiomyocytes.
"These atrial muscle strips represent a great opportunity to model atrial fibrillation in the dish and test drugs," Lemme says. "Nevertheless, improvements can still be made to reach even higher similarity with the human atrial tissue. For us, the next step is to test various means to induce arrhythmias, study mechanisms of electrical remodeling of atrial fibrillation and test new potential drugs."
NOTES FOR EDITORS
Full Study: Marta Lemme, Bärbel M. Ulmer, Marc D. Lemoine, Arne Hansen, Torsten Christ, and Thomas Eschenhagen (2018) "Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium" Stem Cell Reports published 8 Nov 2018 (DOI: 10.1016/j.stemcr.2018.10.008).
View video of the human heart tissue derived from stem cells here.
This research was supported by AFib-TrainNet, the National Research, Development and Innovation Office, the German Ministry of Education and Research (BMBF) and German Centre for Cardiovascular Research, the European Research Council (ERC AG IndivuHeart), the Deutsche Forschungsgemeinschaft, and Leducq Fondation. Thomas Eschenhagen and Arne Hansen are co-founders of EHT Technologies, Hamburg. Godfrey Smith is a founder and executive of Clyde Biosciences Ltd (UK).
Stem Cell Reports, published by Cell Press for the International Society for Stem Cell Research (ISSCR), is a monthly open-access forum communicating basic discoveries in stem cell research, in addition to translational and clinical studies. The journal focuses on shorter, single-point manuscripts that report original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. Visit: cell.com/stem-cell-reports
Carly Britton, Media Contact, Cell Press News, USA (email@example.com; +1 617 397-2863).